Bristol-Myers Squibb
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Bristol-Myers Squibb sits in the top decile of US sponsors by registered trial count (#32 of 15,742 sponsors by registered trial count).
Bristol-Myers Squibb: 1,025 sponsored US clinical trials, 73 recruiting.
Bristol-Myers Squibb sponsors 1,025 registered US clinical trials on ClinicalTrials.gov, 73 of them currently recruiting, and 789 completed. 242 of these trials are in Phase 3-4 (later-stage) and 675 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is HIV Infections, with 20 trials.
Top-decile sponsor footprint
Bristol-Myers Squibb ranks in the top decile of sponsors by registered trial count (#32 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
789 of 892 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,025 total, page 4 of 21
A Study to Evaluate Luspatercept Treatment Patterns and Outcomes in Erythropoiesis-Stimulating Agents-Naïve Patients With Lower-Risk Myelodysplastic Syndromes in the United States
NCT06851065
A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies
NCT05209295
A Study Evaluating Deucravacitinib Concentrations in the Breast Milk and Plasma of Healthy Lactating Female Participants
NCT06476834
Study to Assess Drug Levels and Safety of BMS-986278 in Healthy Participants and Participants With Different Degrees of Hepatic Impairment
NCT06425198
A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment
NCT06352528
Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients
NCT06345183
A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants
NCT06144697
A Study to Assess the Relative Bioavailability of 5 mg Mavacamten Opened Capsule Administered Via Nasogastric Tube Compared to Intact Oral 5 mg Mavacamten in Healthy Participants
NCT06211179
A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
NCT06094296
A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors
NCT06024174
A Study to Evaluate the Drug Levels, Metabolism, and Removal of BMS-986322 in Healthy Adult Male Participants
NCT06088264
A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986446 in Healthy Participants and Healthy Participants of Japanese Ethnicity
NCT06084598
A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis
NCT06042920
Incidence of Hyperpigmentation in Black Patients With Multiple Myeloma Treated With Immunomodulatory Drugs
NCT06160167
A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
NCT06027437
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional Therapy
NCT05470985
A Study to Evaluate the Drug Levels of Abatacept Converted From Drug Substance by Two Different Processes in Healthy Participants
NCT05981976
A Study to Assess the Effect of Danicamtiv on the Drug Levels of Midazolam in Participants With Stable Heart Failure
NCT05952089
A Study to Evaluate the Drug Levels, Physical and Chemical Changes, and Removal of BMS-986196 in Healthy Male Participants
NCT05981963
A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With Melanoma
NCT06163170
A Study to Assess the Bioavailability and Effect of Food of BMS-986419 Immediate-release Tablet Formulation in Healthy Adult Participants
NCT05963932
A Study to Evaluate Nivolumab in the Treatment of Early Stage Esophageal or Gastroesophageal Cancer
NCT05780736
A Study to Assess the Effect of BMS-986419 on the Single Dose Drug Levels of Probe Substrates in Healthy Participants
NCT05932277
A Study to Assess the Effect of Phenytoin on the Drug Levels of Afimetoran and the Effect of Afimetoran on the Drug Levels of Midazolam
NCT05901714
A Study to Evaluate the Drug-drug Interaction of BMS-986196 With Oral Contraceptives in Healthy Female Participants
NCT05891262
A Study to Evaluate the Drug-drug Interaction Potential of BMS-986196 in Healthy Participants
NCT05852769
A Study to Evaluate Treatment Preferences for Japanese Participants With Muscle-invasive Urothelial Carcinoma of the Bladder
NCT05742867
A Study to Compare the Relative Bioavailability of Two Iberdomide (CC-220) Formulations and to Assess The Effect Of Food on the Drug Levels of Iberdomide in Healthy Adult Participants
NCT05899738
A Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]BMS-986419 in Healthy Male Participants
NCT05847439
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986325 in Healthy Japanese Participants
NCT05813717
A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis
NCT05730725
A Study to Evaluate the Safety, Tolerability, and Drug Levels of Danicamtiv in Healthy Japanese and Caucasian Participants
NCT05806359
A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986447 in Healthy Participants
NCT05760937
Mavacamten in Obstructive Hypertrophic Cardiomyopathy
NCT07168655
A Study to Evaluate the Effects of Mavacamten in Healthy Participants
NCT05719805
A Study of Mezigdomide in Healthy Participants and Participants With Hepatic Impairment
NCT05707390
A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT05613088
A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting
NCT05701995
A Study to Evaluate the Efficacy, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT05556343
A Study to Evaluate the Absorption, Metabolism, and Excretion (ADME) of BMS-986435
NCT05686096
A Study to Assess the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants
NCT05658146
A Study Investigating the Safety, Tolerability, Drug Levels and Drug Effect of BMS-986278 in Healthy Adult Participants (Part 1) and Japanese Participants (Part 2)
NCT05684289
An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice
NCT05369832
A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy
NCT05582395
A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors
NCT05625412
A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)
NCT05577715
A Study Investigating Interactions Between BMS-986322 and Rosuvastatin, Metformin and Methotrexate in Healthy Participants
NCT05615012
A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata
NCT05556265
A Study to Investigate the Interaction of BMS-986322 and a Combined Oral Hormonal Contraceptive (Ethinyl Estradiol [EE]/Norethindrone [NET]) in Healthy Female Participants
NCT05579574
A Study to Evaluate the Metabolism and Excretion of BMS-986369 in Healthy Male Participants
NCT05567510
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 436 |
| Phase 2 | 239 |
| Phase 3 | 213 |
| Phase 4 | 29 |
Therapeutic Areas
What is open in the Bristol-Myers Squibb pipeline
73 recruiting of 1,025 indexed (7% open); 789 completed (77%).
Phase mix: 242 late (III/IV) vs 675 early (I/II) (early-phase heavy).
Top condition: HIV Infections (20 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Bristol-Myers Squibb: open-pipeline peers nationwide
Peers matched on 1,025 registered trials and 7% open enrollment, not the therapeutic-area sidebar.
Bristol-Myers Squibb sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,025 trials (± recruiting share)
- University of Wisconsin, Madison · 1,039 trials · 15% recruiting
- University of Washington · 1,048 trials · 15% recruiting
- University of Minnesota · 966 trials · 19% recruiting
- Columbia University · 958 trials · 18% recruiting
Sponsors near 7% open enrollment (± trial volume)
- Carol Fabian, MD · 7% recruiting · 14 trials
- Celldex Therapeutics · 7% recruiting · 42 trials
- Kaiser Permanente · 7% recruiting · 294 trials
- Mannkind Corporation · 7% recruiting · 42 trials
Related
What to do with this Bristol-Myers Squibb page
1,025 registered trials is a research-attention snapshot, not an endorsement of Bristol-Myers Squibb or any single study.
- 73 of Bristol-Myers Squibb's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- HIV Infections is the condition Bristol-Myers Squibb studies most, compare against other sponsors active in the same condition before evaluating a specific study. See HIV Infections trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Bristol-Myers Squibb pipeline card: 1,025 registered trials from official public datasets.Report a data error.